– USA, MN – Francis Medical, Inc., a medical device company developing an innovative and proprietary water vapor ablation therapy, today announced the appointment of Andrew Cleeland to its board of directors.
“We are thrilled to welcome Andrew Cleeland to the boar. Andrew’s rich experience in healthcare innovation and the successful development and deployment of medical technologies will be invaluable to Francis Medical as we look for Vanquish™ to become the first-line treatment of choice for prostate cancerd,” said Board Chair, André de Bruin.
About Andrew Cleeland
Andrew Cleeland is currently CEO of Fogarty Innovation, a global leader in the invention, development, and deployment of new medical technologies. He has held this position since 2017. Before that, he was VP and general manager of transcatheter mitral valve replacement at Medtronic, a position stemming from the 2015 acquisition of Twelve Inc., where Cleeland had been the president and CEO beginning in 2012. From 2006 to 2012, he served as president and CEO of Ardian, Inc., which was also acquired by Medtronic. Cleeland has also served in leadership roles at Radiant, Baxter, and Telectronics Pacing Systems, and has held board director or chairperson positions for numerous companies, including Zenflow, Medical Microinstruments, Saluda Medical, Medical Device Innovation Consortium, The Foundry, and nVision Medical. He currently serves in an advisory capacity at Arboretum Ventures, Longitude Capital, the UCSF-Stanford Pediatric Device Consortium, and the Agency for Science, Technology, and Research in Singapore. Cleeland received his Bachelor of Applied Science, Biophysics degree from the Swinburne Institute of Technology in Melbourne, Australia.
“Francis Medical has a powerfully simple and differentiated technology, supported by an outstanding team,” said Andrew Cleeland. “I’m excited to add my knowledge and experience to the group and make a meaningful impact as we strive to bring this transformational technology to urologists and their patients.”
About Francis Medical
Francis Medical is committed to developing urological cancer treatments that are tough on cancer and gentle on patients, with a compassionate belief that minimally invasive therapies can effectively treat cancerous tissue. The company’s foundation is a tribute to and legacy of the inventor’s father, Francis Hoey, who endured prostate cancer treatments that had harsh implications on his everyday life before he died from the disease in 1991. Unfortunately, current prostate cancer treatments, which come with side effects like urinary incontinence and erectile dysfunction, are not much different than what Francis Hoey encountered. In contrast, water vapor technology applies the thermal energy stored in sterile water vapor to cancerous tissue via a simple transurethral procedure, potentially minimizing life-altering side effects.
For more information: https://www.francismedical.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.